Welcome to Santa Cruz Biotechnology!

Aurora Kinase/Cdk Inhibitor (CAS 443797-96-4)

  Based on popularity  |  Add your review

Synonym:JNJ-7706621, 4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide
Application:(JNJ-7706621) a cell-permeable, reversible, ATP-competitive kinase inhibitor
CAS Number:443797-96-4
Molecular Weight:435.4
Molecular Formula:C15H12F2N6O3S CH3CN
Refer to Certificate of Analysis for lot specific data (including water content).
Set Currency

 Ordering Information
Product NameCatalog #UnitPriceQtyAddFavorites
Aurora Kinase/Cdk Inhibitor sc-203829 5 mg $440
Aurora Kinase/Cdk inhibitor (JNJ-7706621) is a cell-permeable triazolylsulfonamido compound that acts as a reversible, ATP-competitive kinase inhibitor with selectivity towards ARKs (IC50 = 11 and 15 nM for ARK-1 (Aurora-A) and ARK-2 (Aurora-B), respectively) and Cdk's (IC50 = 9, 4, and 3 nM for Cdc2 (Cdk1)/B, Cdk2/A, and Cdk2/E, respectively). Aurora Kinase/Cdk Inhibitor displays antitumor properties (IC50 in the range of 112-514 nM against various human cancer cell lines).
Technical Information
Physical State:Solid
Solubility:Soluble in DMSO.
Storage:Store at 4° C
IC50:Aurora-A: IC50 = 11 nM; Aurora-B: IC50 = 15 nM; Cdk1/B: IC50 = 9 nM; Cdk2/A: IC50 = 4 nM; Cdk2/E: IC50 = 3 nM; cancer cell lines: IC50 = 112 - 514 nM (human)
Safety and Reference Information
PubChem CID:16760303
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Aurora Kinase/Cdk Inhibitor Product Reviews
There are currently no reviews for Aurora Kinase/Cdk Inhibitor. Add your review!

1. Emanuel, S. et al. 2005. Cancer Res. 65(19): 9038-9046. PMID: 16204078
2. Lin, R. et al. 2005. J. Med. Chem. 48(13): 4208-4211. PMID: 15974571
3. Seamon, J.A. et al. 2006. Mol. Cancer Ther. 5(10): 2459-2467. PMID: 17041089
Certificate of Analysis

Catalog Number

Lot Number

Related Product Categories